New Vaccine For Respiratory Syncytial Virus (RSV) Infections

by Madhumathi Palaniappan on  December 21, 2016 at 5:02 PM Health Watch
RSS Email Print This Page Comment
Highlights
  • Respiratory Syncytial Virus (RSV) can cause upper respiratory tract infections in children.
  • Previous attempts in developing vaccines were found to be inefficient for RSV treatment.
  • Scientists discover new version of the virus to be potent in producing protective antibodies against RSV infections.
A new version of respiratory syncytial virus (RSV) that is highly attenuated and is potent in producing protective antibodies was engineered to develop a new vaccine for RSV infections, finds a study from Emory University School of Medicine and Children's Healthcare of Atlanta.
New Vaccine For Respiratory Syncytial Virus (RSV) Infections
New Vaccine For Respiratory Syncytial Virus (RSV) Infections

The study findings were detailed in the journal Nature Communications.

Martin Moore, Ph.D, associate professor of pediatrics at Emory University School of Medicine and Children's Healthcare of Atlanta Research Scholar said, "Our paper shows that it's possible to attenuate RSV without losing any immunogenicity."

"This is a promising live-attenuated vaccine candidate that merits further investigation clinically."

He also added that the next step of creating the vaccine requires clinical trials to study the safety and immunogenicity of the vaccine.

Respiratory Syncytial virus (RSV) is a common respiratory virus that causes respiratory tract infections like bronchiolitis, pneumonia. It is the number one cause of pneumonia death in children and one of the most important causes of infant hospitalization in the United States.

Previous attempts to develop respiratory syncytial virus in 1960 have backfired, and has worsened RSV infections in infants. Even, a recent clinical trial of protein-only RSV vaccines has shown disappointing results.

Some vaccines against another virus like polio, mumps and measles were created by weakening the virus in cell culture. The strain was considered to be safe for developing the vaccine but was also found to stimulate the immune system.

Moore said, "Achieving that balance is a challenge, "Weakening RSV by passage hasn't worked out satisfactorily. It turns out that for RSV, the natural virus does not induce a lot of immunity itself."

Moore and his team engineered Respiratory syncytial virus to increase the production of a protein called Fusion (F). It is critical for specific virus and is the target for developing several vaccines. Mutations in the gene may encode for the fusion protein. The research team also made the virus more stable to heat, that could help in manufacturing and developing vaccines.

The research team has also removed or weakened other viral genes that promote infections and suppress the immune system. The modified virus is called OE4 stimulated high levels of producing antibodies.

The research team also used the procedure of codon-deoptimization to rewrite the viral genes. This procedure makes it less likely for the virus to change back to its original form.

While examining through the electron microscope, OE4 virions were found to be similar to the standard RSV virions. OE4 proteins had higher levels of immunogenic form of F protein and lower levels of another protein G.

The work was carried in collaboration with Elizabeth Wright, PhD, Emory associate professor of pediatrics and her team at Emory's Robert P. Apkarian Integrated Electron Microscopy Core.

OE4 vaccines can completely protect mice against later infections caused by RSV virus. In contrast, when compared to the chemically inactivated RSV vaccine OE4 did not enhance lung disease in cotton rats. The animal studies were conducted at Baylor College of Medicine and Sigmovir Systems.

Respiratory Syncytial Virus (RSV)
  • It is one of the most common cause of bronchiolitis (inflammation of the airways in the lungs)
  • RSV infections may show symptoms within 4 to 6 days.
  • Children under the age of 2 are at a higher risk for RSV infections.
  • Complications of RSV infections may result in lung failure and pneumonia.
Preventive Measures for Respiratory Syncytial Virus Infections
  • Wash hands before touching the baby.
  • Avoid contact with the baby if you have fever or cold.
  • Do not smoke, as exposure to tobacco may increase the risk of RSV infections.
  • Avoid kissing the baby to prevent RSV infections.
References
  1. Stobert.et.al. 'A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation' Nature Communications ; (2016) doi:10.1038/ncomms13916
  2. Respiratory Syncytial Virus Infection (RSV) - (https:www.cdc.gov/rsv/about/infection.html )
  3. Respiratory syncytial virus (RSV) - (https:medlineplus.gov/ency/article/001564.htm)


Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Chicken Pox Shigellosis Asbestosis Vaccination for Children Top 10 Vaccine Myths Debunked 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive